Glaucoma Market Size, Share, Trends, Growth Outlook

Glaucoma Market is estimated to increase at a growth rate of 6.1% CAGR over the forecast period from 2024 to 2030.

The Glaucoma Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Disease (Open Angle Glaucoma, Angle Closure Glaucoma, Others), By Drug Class (Prostaglandins Analogs, Beta-blockers, Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).

An Introduction to Glaucoma Market in 2024

The Glaucoma market in 2024 serves the demand for diagnostic tools, pharmaceuticals, and surgical interventions aimed at managing and treating glaucoma, a progressive optic neuropathy characterized by elevated intraocular pressure (IOP), optic nerve damage, and visual field loss leading to irreversible blindness if left untreated. Glaucoma therapeutics include intraocular pressure-lowering medications such as prostaglandin analogs, beta-blockers, alpha agonists, and carbonic anhydrase inhibitors, as well as surgical procedures such as trabeculectomy, laser trabeculoplasty, and minimally invasive glaucoma surgeries (MIGS) aimed at improving aqueous humor outflow and reducing IOP. Market dynamics are driven by factors such as the increasing prevalence of glaucoma and age-related eye diseases, advancements in diagnostic imaging and visual field testing, and the demand for innovative and minimally invasive treatment options for glaucoma patients. Collaboration between ophthalmologists, optometrists, pharmaceutical companies, and medical device manufacturers drives innovation and market growth in the glaucoma market, supporting improved disease detection, management, and preservation of vision for individuals at risk of glaucomatous optic neuropathy.

Glaucoma Market Trend: Shift Towards Minimally Invasive Glaucoma Surgery (MIGS)

A prominent trend in the glaucoma market is the shift towards minimally invasive glaucoma surgery (MIGS). MIGS procedures offer a less invasive alternative to traditional glaucoma surgeries, with reduced risk, shorter recovery times, and fewer complications. As patients and ophthalmologists seek safer and more effective treatment options for glaucoma management, there is increasing adoption of MIGS devices and techniques such as trabecular micro-bypass stents, suprachoroidal shunts, and micro-invasive laser procedures. This trend is driven by the desire to improve patient outcomes, enhance quality of life, and reduce the burden of medication compliance and long-term management associated with traditional glaucoma treatments.

Glaucoma Market Driver: Growing Aging Population and Increasing Prevalence of Glaucoma

A key driver in the glaucoma market is the growing aging population and increasing prevalence of glaucoma. Glaucoma is a leading cause of irreversible blindness worldwide, particularly among older adults, with the risk of developing glaucoma increasing with age. As the global population ages, the number of individuals affected by glaucoma is expected to rise, driving demand for glaucoma diagnosis, treatment, and management services. This driver is further fueled by factors such as changing demographics, rising awareness of glaucoma risk factors, and advancements in diagnostic technologies that enable earlier detection and intervention, highlighting the need for innovative approaches to glaucoma care and disease management.

Glaucoma Market Opportunity: Development of Novel Drug Delivery Systems for Glaucoma Treatment

An opportunity for growth in the glaucoma market lies in the development of novel drug delivery systems for glaucoma treatment. While topical eye drops are the primary mode of pharmacological therapy for glaucoma, they are associated with challenges such as poor patient adherence, ocular surface toxicity, and limited efficacy due to low bioavailability and rapid clearance from the ocular surface. By developing innovative drug delivery technologies such as sustained-release implants, punctal plugs, microneedle patches, or injectable formulations, pharmaceutical companies can overcome these challenges and improve the efficacy, safety, and convenience of glaucoma treatment. This opportunity aligns with the increasing demand for patient-friendly treatment options that enhance medication adherence, reduce treatment burden, and optimize long-term outcomes for glaucoma patients, positioning drug delivery innovation as a key area for advancement and differentiation in the competitive landscape of glaucoma therapeutics.

Glaucoma Market Segmentation

By Disease
Open Angle Glaucoma
Angle Closure Glaucoma
Others
By Drug Class
Prostaglandins Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Glaucoma Market Companies

AbbVie Inc
Akron Operating Company LLC
Alcon Inc
Bausch + Lomb Corp
Novartis AG
Pfizer Inc
Santen Pharmaceutical Co. Ltd
Teva Pharmaceuticals Industries Ltd
Thea Pharma

 

 

Reasons to Buy the Glaucoma Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Glaucoma Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Glaucoma Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Glaucoma Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Glaucoma Market Size Outlook, $ Million, 2021 to 2030
3.2 Glaucoma Market Outlook by Type, $ Million, 2021 to 2030
3.3 Glaucoma Market Outlook by Product, $ Million, 2021 to 2030
3.4 Glaucoma Market Outlook by Application, $ Million, 2021 to 2030
3.5 Glaucoma Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Glaucoma Market Industry
4.2 Key Market Trends in Glaucoma Market Industry
4.3 Potential Opportunities in Glaucoma Market Industry
4.4 Key Challenges in Glaucoma Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Glaucoma Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Glaucoma Market Outlook By Segments
7.1 Glaucoma Market Outlook by Segments
By Disease
Open Angle Glaucoma
Angle Closure Glaucoma
Others
By Drug Class
Prostaglandins Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

8 North America Glaucoma Market Analysis And Outlook To 2030
8.1 Introduction to North America Glaucoma Markets in 2024
8.2 North America Glaucoma Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Glaucoma Market size Outlook by Segments, 2021-2030
By Disease
Open Angle Glaucoma
Angle Closure Glaucoma
Others
By Drug Class
Prostaglandins Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

9 Europe Glaucoma Market Analysis And Outlook To 2030
9.1 Introduction to Europe Glaucoma Markets in 2024
9.2 Europe Glaucoma Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Glaucoma Market Size Outlook By Segments, 2021-2030
By Disease
Open Angle Glaucoma
Angle Closure Glaucoma
Others
By Drug Class
Prostaglandins Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

10 Asia Pacific Glaucoma Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Glaucoma Markets in 2024
10.2 Asia Pacific Glaucoma Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Glaucoma Market size Outlook by Segments, 2021-2030
By Disease
Open Angle Glaucoma
Angle Closure Glaucoma
Others
By Drug Class
Prostaglandins Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

11 South America Glaucoma Market Analysis And Outlook To 2030
11.1 Introduction to South America Glaucoma Markets in 2024
11.2 South America Glaucoma Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Glaucoma Market size Outlook by Segments, 2021-2030
By Disease
Open Angle Glaucoma
Angle Closure Glaucoma
Others
By Drug Class
Prostaglandins Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

12 Middle East And Africa Glaucoma Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Glaucoma Markets in 2024
12.2 Middle East and Africa Glaucoma Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Glaucoma Market size Outlook by Segments, 2021-2030
By Disease
Open Angle Glaucoma
Angle Closure Glaucoma
Others
By Drug Class
Prostaglandins Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Akron Operating Company LLC
Alcon Inc
Bausch + Lomb Corp
Novartis AG
Pfizer Inc
Santen Pharmaceutical Co. Ltd
Teva Pharmaceuticals Industries Ltd
Thea Pharma

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Disease
Open Angle Glaucoma
Angle Closure Glaucoma
Others
By Drug Class
Prostaglandins Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy